Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
PODCAST | Deals

Alnylam-Roche deal, plus insights on the IRA, FTC: a BioCentury podcast

How Alnylam deal fits biotech’s growth strategy. Plus: latest developments in IRA litigation and FTC M&A guidelines 

By Jeff Cranmer, Executive Editor
July 25, 2023 1:12 AM UTC

A hypertension deal with Roche (SIX:ROG; OTCQX:RHHBY) will help Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) execute on its growth strategy of moving into more prevalent diseases. On the latest BioCentury This Week podcast, BioCentury’s editors discuss what the deal does for both companies and why plans for a cardiovascular outcomes trial (CVOT) before the launch of zilebesiran are critical for maximizing the program’s commercial opportunity.

BioCentury’s editors also preview this week’s episode of The BioCentury Show, in which Washington Editor Steve Usdin speaks with Alkermes plc (NASDAQ:ALKS) Chairman and CEO Richard Pops about the politics and policy environment around drug pricing and the Inflation Reduction Act and assess the latest developments in industry litigation against the IRA and new FTC guidelines on antitrust rules.

For information on how to sponsor BioCentury This Week and The BioCentury Show, please contact Sarah Shoaff at sarah.shoaff@biocentury.com.

Purchase Reprint/Distribution Rights
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article